University of Utah Technology Licensing Office: Bioparin STTR Grant
source confidence: Medium status: Useful updated 2026-06-19
Summary
The University of Utah Technology Licensing Office describes Bioparin as a university spinout developing synthetic heparin and reports a $306,000 Phase I Small Business Technology Transfer grant supporting scale-up work.
Useful Claims
- Bioparin is a University of Utah spinout.
- The university reports that Bioparin received a $306,000 Phase I STTR grant.
- The company aims to develop synthetic heparin as an alternative to animal-sourced production.
- The grant supports large-scale heparin biomanufacturing work.
Verbatim
Bioparin, a University of Utah spinout, just received a $306,000 Phase I Small Business Technology Transfer (STTR) grant, a federal funding program that supports small businesses collaborating with research institutions to bring innovative technologies to market, to advance its groundbreaking work in synthetic heparin production.
Locator: article body, introductory section.
Bioparin aims to eliminate reliance on animal-sourced heparin by developing a synthetic variant that offers greater safety, consistency, and availability.
The STTR grant will support large-scale heparin biomanufacturing, a challenge that has yet to be tackled.
Locator: “Bioparin’s Solution: A Reliable, Scalable Alternative.”
Reliability Notes
This is an official university commercialization story, not Bioparin's own website or the federal award record. It is useful for the university relationship and the university's account of the grant, but the award amount and phase should ultimately be joined to the issuing federal record. It does not establish a founding year, headquarters, current operating status, or venture financing.